0000899243-22-018432.txt : 20220517
0000899243-22-018432.hdr.sgml : 20220517
20220517172709
ACCESSION NUMBER: 0000899243-22-018432
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220515
FILED AS OF DATE: 20220517
DATE AS OF CHANGE: 20220517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NEUMANN CLARKE
CENTRAL INDEX KEY: 0001321466
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39334
FILM NUMBER: 22936012
MAIL ADDRESS:
STREET 1: 3595 JOHN HOPKINS CT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER NAME:
FORMER CONFORMED NAME: Neumann Clarke
DATE OF NAME CHANGE: 20050323
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIORA THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001580063
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 273950390
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4330 LA JOLLA VILLAGE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92122
BUSINESS PHONE: 855-293-2639
MAIL ADDRESS:
STREET 1: 4330 LA JOLLA VILLAGE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92122
FORMER COMPANY:
FORMER CONFORMED NAME: PROGENITY, INC.
DATE OF NAME CHANGE: 20150617
FORMER COMPANY:
FORMER CONFORMED NAME: ASCENDANT MDX, INC.
DATE OF NAME CHANGE: 20130625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-15
0
0001580063
BIORA THERAPEUTICS, INC.
BIOR
0001321466
NEUMANN CLARKE
C/O BIORA THERAPEUTICS, INC.
4330 LA JOLLA VILLAGE DRIVE, SUITE 300
SAN DIEGO
CA
92122
0
1
0
0
See Remarks
Common Stock
2022-05-15
4
F
0
8305
0.75
D
308320
D
Common Stock
2022-05-15
4
A
0
239962
0.00
A
548282
D
Stock Option (Right to Buy)
0.75
2022-05-15
4
A
0
387752
0.00
A
2032-05-15
Common Stock
387752
387752
D
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 24,014 vested restricted stock units on May 15, 2022.
Consists of 239,962 restricted stock units, 25% of which will vest on May 15, 2023, with the remaining shares vesting in equal semi-annual installments through May 15, 2026, subject to the Reporting Person's continued service to the Issuer.
This option represents the right to purchase 387,752 shares of the Issuer's common stock, 8,078 of which vested upon grant, with the remaining shares vesting in equal monthly installments through April 15, 2026, subject to the Reporting Person's continued service to the Issuer.
Senior Vice President, General Counsel and Secretary
/s/ Will Pridgen, Attorney-in-Fact for Clarke Neumann
2022-05-17